



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/664,991	09/16/2003	Leonard F. Bjeldanes	B03-074-1	4613
23379	7590	02/21/2008		
RICHARD ARON OSMAN			EXAMINER	
4070 CALLE ISABELLA			BETTON, TIMOTHY E	
SAN CLEMENTE, CA 92672				
			ART UNIT	PAPER NUMBER
			1617	
			NOTIFICATION DATE	DELIVERY MODE
			02/21/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

RICHARD@SCI-TECH.COM
jan@sci-tech.com

Office Action Summary	Application No.	Applicant(s)
	10/664,991	BJELDANES ET AL.
	Examiner Timothy E. Betton	Art Unit 1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 08 September 2007.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-22 is/are pending in the application.
 4a) Of the above claim(s) 8-14 and 20-22 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-7 and 15-19 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Applicants' Remarks and Declaration filed 8 September 2007 have been acknowledged and duly made of record.

Applicants' argue the properness drawn to alleged lack of applicable prior art by Nachschon-Kedmi reference. Further applicants' argue the relevance of the Safe et al, the secondary reference.

In view of said arguments made by applicants', the Remarks have been considered but are not found persuasive.

The applicants' provide no evidence of a filing date which pre-dates the Nachschon-Kedmi reference. Applicant's filing date is officially recorded as 16 September 2003. The Nachschon-Kedmi reference is cited as June 2003 publication, which is sufficiently postdated by applicant's filing date.

Secondly, The Safe et al. reference teaches similar subject matter in relation to claimed invention as only in the alternative a general DIM administration to inhibit the proliferation of androgen-independent cells. The skilled artisan would instantly be inclined to recognize that applicants' alleged discovery of finding that DIM is a potent antiandrogen would be quite identical to Safe's disclosure which teaches DIM can inhibit the proliferation of androgen-independent cells.

Further, instant claim 1 discloses the limitation drawn to the detecting of a resultant antiandrogenic response in the host. This is interpreted broadly based on the general context in which the term antiandrogenic is disclosed. A resultant response of an antiandrogenic nature is

Art Unit: 1617

not elucidated or described in the instant specification in such a way as to clearly convey to the skilled artisan the scope of the claimed invention. The inventive objective of the invention is not clear because of the general implication of the term *antiandrogenic*.

The declaration filed on 1 May 2007 under 37 CFR 1.131 has been considered but is ineffective to overcome the Nachschon-Kedmi reference.

The evidence submitted is insufficient to establish diligence from a date prior to the date of reduction to practice of the Nachschon-Kedmi reference to either a constructive reduction to practice or an actual reduction to practice. The evidence is not commensurate in scope with the claims without an explanation supporting such findings is unacceptable.

Evidence of fact is supported in the instance that one of the named inventors is indicated as the leading author of the publication as disclosed in the instant declaration. However, evidence of fact is absent in regard to comparative test results, correlative data, synthetic representation of possession of the invention, etc. Accordingly, the mere disclosure that the secondary reference teaches no more than the inventors' prior publications is erroneous in view of prevailing evidence that an appropriate filing date is the requirement for possession of an invention.

Thus, applicants' statement drawn to preparing, reviewing, and revising is unsupported and there are no explanations or conclusory statements supported by factual evidence (3rd paragraph).

Specifically, applicants' purport in the instant declaration that the said applicants' were in possession of the claimed subject matter between the March 27, 2003 to September 16, 2003. Substantive evidence supporting applicants' allegations of preparing, reviewing, revising, with the exception of filing is absent in the instant declaration, specifications and current claims. The

Art Unit: 1617

embodiments contained within the instant declaration are drawn primarily to the chemical compound DIM which appears to differ in the inventive objective of what the scope of the instant claims intends.

For the reasons given above in response to applicants' Remarks, the 103(a) rejection is maintained.

Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant invention.

Claim Rejections – 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-7 and 15-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nachshon-Kedmi et al. in view of Safe (PGPUB 2002/0115708 A1).

Nachshon-Kedmi et al. teach a cell-line study directed toward the apoptotic effects of ¹³C and DIM on prostate cancer cells (Abstract, page 747, 1st column).

Distinct biochemical and morphological features, including cell shrinkage, characterize the apoptotic process. Cell shrinkage is a physiological occurrence, which, to the ordinary,

Art Unit: 1617

skilled artisan would constitute a form of reduction as antiandrogenic response (page 750, column 2, lines 6-10).

Nachshon-Kedmi et al. teach prostate hyperplasia cell lines with variable differences in p53 status (page 746). The p53 gene is significantly involved in the regulative aspect of the apoptotic process (page 752, column 1, last paragraph)

Additionally, said reference makes the claimed invention obvious via the explanation of Western blot analysis, i.e., the determining, contacting, and reducing method steps of claimed invention (page 747).

Further, said reference teaches the actual process by which apoptosis occurs. Principally, during apoptosis, PARP is cleaved from its precursor having a mass of 116kDa, to yield an 85-kDa fragment. There is cleavage in PARP in all cell lines, but to varying degrees. The skilled artisan would at once recognize the reduction of cellular matter via the marked mass decrease from 116kDa to 85kDa.

Safe teaches methods and compositions for the treatment of a wide array of cancers and tumors. In illustrative embodiments, diindolylmethanes, C-substituted diindolylmethanes, and analogs thereof have been described, which when administered either alone, or in combination with other anti-cancer or anti-tumorigenic compounds, provide new therapies for the treatment of prostate cancer (Abstract, [0050], last line of instant paragraph).

Safe teaches a practicing administration (in vitro and in vivo) to human patients in need thereof via inhibition of prostate cancer cell growth [0065, 0049]. Safe discloses the directed use of DIM and derivatives thereof for the specific contacting, detecting, and inhibiting via a gel mobility shift assay for prostate cancer cells (Brief description of Drawings – Table CWU –

Art Unit: 1617

DRTL (1)) in a comparative study to estrogen-dependent pathologies. Safe further discloses the practicing methods of administering said antiandrogenic agent in claims 16, 34, 51, and 69, therein.

Safe teaches derivatives of the practicing DIM core structure that are also taught in the instant application. In said referenced publication on page 3, section [0039] under the heading: Definitions, said structure is disclosed. Derivatives of the core structure are disclosed in the instant application on page 3 of the specification under the heading: Summary of Invention. Safe discloses in published claims, the *in vitro* method (by use of assays which are disclosed empirical series of method steps used to detect a reaction) of treating cancer, the method comprising obtaining a mammal comprising cancer cells, and administering to the mammal a composition comprising an effective dose of a compound of the said formula. Claims 17-19 are made obvious over claims 16, 34, 51, and 69 in Safe obvious over using this related core structure in the use of treatment against the specific cancer-types, i.e., prostate cancer and pathologies thereof.

Safe teaches detection on page 5, Example 2, section [0058] in that a process is disclosed where inhibition was determined, i.e., where clear proliferation of cancer cell lines were significantly inhibited. Further, detection is implied in said reference where sensitive cells were noticeably inhibited at the lowest concentration.

Safe, in accordance, more specifically teaches detection on page 4, section [0047] of said referenced publication where resolution of the mixture using chiral chromatography column would result in the isolation of purified or pure enantiomers products. Furthermore, Safe teaches the use of thin-layer chromatography and liquid chromatography in section [0067] (page 6), both well-established detection methods and/or detection facilitators.

Thus, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine together the teachings and methods of Nachshon-Kedmi et al. and Safe. The skilled artisan would have at once recognized the reasonable expectation of success if the teachings and methods of Nachshon-Kedmi et al. were combined with the teachings of Safe. Safe suggests and supports the motivation to combine via the disclosure of particular limitations, which make the instant set of claims obvious. Likewise, the motivation to combine both references would have been obvious and proper to one of ordinary skill due to overlap of core compounds, assaying methods, and goal of regimen.

It is well known in the art that 13C and DIM (a predominant conversion product of I3C) is a potent antiandrogenic. Therefore, It would have been *prima facie* obvious to combine that, which is taught in Nachshon-Kedmi et al. with that which is taught by Safe to result in the practice of the limitations of claimed invention.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Timothy E. Betton whose telephone number is (571) 272-9922. The examiner can normally be reached on Monday-Friday 8:30a - 5:00p. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

TEB



**SHENGJUN WANG
PRIMARY EXAMINER**